An observational study in Staphylococcus Aureus Infections, sponsored by Mayo Clinic. Withdrawn at 1 site in United States. Per ClinicalTrials.gov, last updated 2018-02-13.
Sponsored by Mayo Clinic · Observational
The objective of this study is to evaluate the impact of the Alere\™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.
273 studies on the registry are indexed under Staphylococcal Infections; 29 are open to participants now.
Browse Staphylococcal Infections studies →Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.
Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S. aureus cultures between Sept 15, 2012 - Dec 31, 2012 (control) and Sept 15, 2013 - Dec 31, 2013 (intervention)
Exclusion criteria:
Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.
Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.
Time (hours) to optimal antimicrobial therapy for patients with MSSA and MRSA infections in the pre-intervention and post-intervention periods
Time frame: within first 7 days of culture result
Time (in hours) to identification of MRSA.
Time frame: within first 3 days of culture result
Vancomycin days of therapy following S. aureus culture result
Time frame: during the 2 weeks following culture result
Proportion of patients with MSSA infection who are switched from an MRSA-active drug to an MSSA-active drug .
Time frame: within 48 hours of Gram-stain result
Duration of bacteremia in patients with MSSA or MRSA bloodstream infections
Time frame: within first 30 days of culture result
Time to contact isolation in patients with MRSA infections
Time frame: within first 7 days of culture result
Length of hospitalization
Time frame: from time of culture result to hospital discharge, an expected average duration of 4 weeks
Total healthcare costs (broken down by bed, laboratory, and pharmacy costs).
participants will be followed for the duration of hospital stay following positive culture result, an expected average of 4 weeks.
Time frame: from time of culture result to time of hospital discharge, an expected average duration of 4 weeks
Proportion of patients where a electronic (P-care) rule flagged for discordant therapy for the PBP2a result
Time frame: within first 3 days after culture result
Proportion of patients where the pharmacist contacted the service to modify therapy
Time frame: wihtin first 7 days after culture result
This study is withdrawn, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayo Clinic